To determine the interaction between central adrenergic and vasopressinergic mechanisms in the regulation of cardiovascular function, the effects of intracerebroventricular (i.c.v.) administration of the α1-agonists, methoxamine and phenylephrine, in conscious Long-Evans (LE) rats were compared with those in Brattleboro rats with hereditary hypothalamic diabetes insipidus (Dl). In LE rats, both i.c.v. methoxamine and phenylephrine increased mean arterial pressure (MAP) and decreased heart rate (HR) in a dose-related manner, while they had no effect on MAP and HR in DI rats within the dose range of 3-30 µg/kg. Both i.c.v. methoxamine (10 µg/kg) and phenylephrine (30 µg/kg) also increased plasma levels of arginine vasopressin (AVP) in LE rats from 2.6 ± 0.4 (n=9) to 22.4 ± 3.5 (n=6, P<0.01) and 37.0 ± 4.0 pg/ml (n=6, P<0.01), respectively, without affecting plasma renin activity (PRA) and plasma angiotensin II (ANG II) levels. Central α1-adrenoceptor stimulation increases vasopressin release from the posterior pituitary, which in part is responsible for the hypertensive and bradycardic responses. However, central vasopressinergic pathways have also been shown to be involved in these cardiovascular effects. Neither i.c.v. nor intravenous (i.v.) infusion of AVP restored the cardiovascular response to i.c.v. α1-agonists in DI rats. In LE rats, however, i.v. pretreatment with the specific vascular antagonist to the pressor effect of AVP, d(CH2)5Tyr(Me)AVP (VP-ANT; 10 µg/kg), significantly attenuated, but did not completely block the hypertensive and bradycardic effects of i.c.v. methoxamine and phenylephrine. In contrast, i.c.v. pretreatment with an AVP antagonist (300 ng/kg) did not modulate the cardiovascular response to i.c.v. methoxamine or phenylephrine. The hypertensive and bradycardic effects of i.c.v. methoxamine and phenylephrine were demonstrated to be of α1-adrenergic specificity, as they were abolished by pretreatment with phentolamine and prazosin but not by yohimbine. The present study clearly demonstrates that endogenous AVP plays a significant role in the cardiovascular responses to central α-adrenergic activation.